[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer]
| Autor: | V F, Semiglazov, V V, Semiglazov, G A, Dashian, E K, Zhil'tsova, V G, Ivanov, A A, Bozhok, E E, Tonuzov, R M, Paltuev, O A, Mel'nikova, A A, Klettsel', P V, Krivorot'ko, R V, Donskikh, I A, Kochetova, A O, Damenia, K Iu, Zernov, D A, Voskresenskiĭ, L M, Bershteĭn |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Aged
80 and over Antineoplastic Agents Hormonal Paclitaxel Aromatase Inhibitors Breast Neoplasms Anastrozole Middle Aged Triazoles Neoadjuvant Therapy Androstadienes Postmenopause Treatment Outcome Receptors Estrogen Doxorubicin Antineoplastic Combined Chemotherapy Protocols Nitriles Humans Female Receptors Progesterone Aged Mammography |
| Zdroj: | Voprosy onkologii. 53(4) |
| ISSN: | 0507-3758 |
| Popis: | Data are presented on a randomized study (stage II) which was undertaken to assess the efficacy of neoadjuvant chemotherapy (doxorubicin+paclitaxel) vis-a-vis endocrine therapy with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive tumors. Preoperative neoadjuvant chemotherapy was well tolerated and showed similar rates of overall response as compared with the latter regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|